Sensitivity of anti-SARS-CoV-2 nucleocapsid protein antibody for breakthrough infections during the epidemic of the Omicron variants

Affiliations

• ¹ Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo 162-8655, Japan. Electronic address: mizoue@hosp.ncgm.go.jp.
• ² Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo 162-8655, Japan.
• ³ Department of Laboratory Testing, Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan.
• ⁴ Infection Control Office, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan.
• ⁵ Infection Control Office, Kohnodai Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan.
• ⁶ Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan.
• ⁷ Kohnodai Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan.
• ⁸ Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
• ⁹ Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.